
Syngene Intl. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Syngene Intl. management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Syngene Intl. management said on order book — free account, 30 seconds.
Capex plans
Track Syngene Intl. — get its next earnings analysis in your feed
How does Syngene Intl. rank vs peers in Healthcare Services?
Pro featureHow does Syngene Intl. rank in Healthcare Services?
Compare Syngene Intl. against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.
Continue your research
What Syngene Intl.'s management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
- Indegene Ltd (Q2 FY27)
Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo